Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7472591 | 1.00 | LMNA (0.42) | LMNACHRM1AURKATP53SLC22A1 | |
| SCHEMBL7313894 | 0.92 | LMNA (0.44) | LMNACHRM1AURKATP53SLC22A1 | |
| SCHEMBL7307232 | 0.92 | LMNA (0.44) | LMNACHRM1AURKATP53SLC22A1 | |
| SCHEMBL7473846 | 0.88 | LMNA (0.45) | LMNACHRM1AURKASLC22A1ABCB11 | |
| SCHEMBL7473843 | 0.88 | LMNA (0.45) | LMNACHRM1AURKASLC22A1ABCB11 | |
| SCHEMBL11371119 | 0.82 | LMNA (0.42) | LMNACHRM1AURKATP53SLC22A1 | |
| SCHEMBL11371073 | 0.82 | LMNA (0.42) | LMNACHRM1TP53SLC22A1ABCB11 | |
| SCHEMBL11366439 | 0.82 | LMNA (0.42) | LMNACHRM1TP53SLC22A1ABCB11 | |
| SCHEMBL11371076 | 0.82 | LMNA (0.42) | LMNACHRM1TP53SLC22A1ABCB11 | |
| SCHEMBL11366435 | 0.82 | LMNA (0.42) | LMNACHRM1TP53SLC22A1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1105392-B1 | PROCESS FOR THE PREPARATION OF IMIDAZODIAZEPINE INTERMEDIATES | ABBOTT LAB (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-1199308-A2 | Process for the preparation of imidazodiazepine intermediates | Abbott Laboratories (US) | 2002-04-24 | — | — | EP | disclosed |
| US-20010014738-A1 | PROCESS FOR THE PREPARATION OF IMIDAZODIAZEPINE INTERMEDIATES | ABBOTT LABORATORIES | 2001-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014738-A1 | PROCESS FOR THE PREPARATION OF IMIDAZODIAZEPINE INTERMEDIATES | CYP3A4, CYP4B1, CYP4A11 | LMNA 1461/4885CHRM1 512/4885AURKA 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.